Sonata Biosciences Inc — Department of Health and Human Services SBIR Phase I: 400
Sonata Biosciences Inc — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $465,696
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 400
- Solicitation
- PA11-215
- NAICS
- —
- Place of performance
- CA
- Period
- 2014-09-08 → 2017-06-30
Description
DESCRIPTION provided by applicant In this proposal we seek to develop a new method and instrument to reduce the complexity of protein mixtures derived from human fluids with an eye to discovery of very low abundance protein biomarkers The proposed method accomplishes two tasks it reduces the dynamic range of the protein mixture by three or more orders of magnitude and it concentrates proteins by a factor of or more so that low abundance can be detected and concentration differences noted The method does not use antibodies combinatorial peptide libraries carrier ampholytes or solid liquid adsorption equilibria such as HPLC The samples produced are compatible with D gel electrophoresis and D liquid chromatography tandem mass spectrometry approaches By using different physical methods to separate the protein mixtures the goal is to uncover new biomarkers that have eluded existing state of the art methods After development the proposed method and instrument will be demonstrated using human plasma where a sample from a lung cancer patient is compared with a reference that does not have cancer Additional low abundance proteins that are potential biomarkers will be uncovered when compared with traditional immunodepletion methods PUBLIC HEALTH RELEVANCE Proteomics is a powerful approach that can be used to assess the state of a cell tissue or organism This proposal seeks to develop a method and instrument to simplify complex protein mixtures derived from human fluids that delves deeper into the proteome than existing state of the art methods The goal is to uncover very dilute proteins that indicate disease It is intended as a research tool and not one for the clinic and the results would be used to create diagnostic tests using traditional methods It would affect the fields of discovery of diagnostic markers to identify and development of pharmaceuticals that are used to treat disease